Dark

Check out our Dark Pool Levels

PDLI
PDL BioPharma, Inc. Common Stock
stock NASDAQ

Inactive

Dec 30, 2020 3:59:00 PM EST

2.48USD-8.487%(-0.23)2,353,432

Pre-market

0.00USD-100.000%(-2.68)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 24, 2020

05:55AM EST PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 1,565,000 Shares @ Avg Price of $2.60/Share in Form 4 Filing on Wednesday Benzinga

Dec 16, 2020

05:58AM EST PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 2,090,000 Shares @ Avg Price of $2.57/Share in Form 4 Filing on Tuesday Benzinga

Dec 14, 2020

08:41AM EST PDL BioPharma Reports $51.4M Capital Provision Deal With Epps Investments Related To Co.'s Previously-Announced Settlement Deal With Wellstat Benzinga

08:36AM EST PDL BioPharma Enters $51.4M Capital Provision Agreement With Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement With Wellstat Benzinga

08:36AM EST PDL BioPharma Enters Capital Provision Agreement With Epps Investments LLC RTTNews

08:31AM EST Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat PR Newswire

Dec 8, 2020

04:10PM EST PDL Announces Timeline for Voluntarily Delisting from Nasdaq; Sets Date For Dec. 31, 2020 Benzinga

04:08PM EST PDL Announces That It Volybtarily Be Delisting From The Nasdaq On Or About December 28, 2020 Benzinga

04:06PM EST PDL Announces Timeline for Voluntarily Delisting from Nasdaq PR Newswire

Nov 12, 2020

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

04:34PM EST Recap: PDL BioPharma Q3 Earnings Benzinga

04:14PM EST PDL BioPharma Plans To File A Certificate Of Dissolution With The State Of Delaware On January 4, 2021; Stock Is Expected To Be Delisted From Nasdaq After December 31, 2020 Benzinga

04:10PM EST PDL BioPharma EPS For Two Months Ended August 31, 2020 Total $0.04 RTTNews

04:07PM EST PDL BioPharma Q3 EPS $0.04 Misses $0.06 Estimate, Sales $4.12M Miss $5.50M Estimate Benzinga

04:06PM EST PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To PR Newswire

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 9, 2020

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

05:27PM EST PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business PR Newswire

Oct 29, 2020

08:02AM EDT PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a PR Newswire

Oct 2, 2020

08:31AM EDT PDL BioPharma Completes Spin-off Of Its Femtosecond Laser System Business, LENSAR RTTNews

08:30AM EDT PDL BioPharma Completes Spin-Off of LENSAR PR Newswire

Sep 10, 2020

08:47AM EDT PDL BioPharma Inc. (PDLI) said its Board has approved the separation of LENSAR Inc., a majority owned subsidiary of PDL, from PDL in the form of a dividend involving the distribution of all outstanding shares of LENSAR common stock owned by PDL to holders of PDL common stock. RTTNews

08:39AM EDT PDL BioPharma Says To Complete Spin-Off Of LENSAR, Inc. On October 1, 2020 Benzinga

08:32AM EDT PDL BioPharma To Complete Spin-Off Of LENSAR On October 1, 2020 RTTNews

08:31AM EDT PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020 PR Newswire

Sep 9, 2020

09:08AM EDT PDL BioPharma, Inc. (PDLI) announced the closing of the sale of its subsidiaries Noden Pharma DAC and Noden Pharma USA to Stanley Capital. This will result in payments to PDL of up to $52.83 million in cash, $4.58 million greater than previously announced. Payments to PDL, in connection with the closing of the deal, are $12.72 million. RTTNews

08:32AM EDT PDL BioPharma Says Closes Sale Of Noden Pharma DAC And Noden Pharma USA To Stanley Capital RTTNews

08:31AM EDT PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to PR Newswire

Aug 31, 2020

09:05AM EDT PDL BioPharma Reports Sale Of Three Royalty Interests For Kybella, Zalviso And Coflex To SWK Funding, LLC RTTNews

09:05AM EDT PDL BioPharma Reports Sale Of Kybella, Zalviso, Coflex Royalties To SWK Holdings For $4.35M In Cash Benzinga

09:02AM EDT PDL BioPharma Announces Sale of Kybella(r), Zalviso(r) and Coflex(r) Royalties PR Newswire

Aug 26, 2020

09:05AM EDT PDL BioPharma Files Form 10 Registration Statement With SEC For Potential Spin-off Of LENSAR RTTNews

09:03AM EDT PDL BioPharma Announces Filing Of A Form 10 Registration Statement With SEC For Potential Spin-off Of LENSAR To PDL's Stockholders Benzinga

09:02AM EDT Securities and Exchange Commission for a Potential Spin-off of LENSAR to PDL's Stockholders PR Newswire

Aug 12, 2020

08:44AM EDT PDL BioPharma, Inc. (PDLI) has entered into a settlement agreement with related entities of Defined Diagnostics, LLC, or Wellstat Parties, resolving litigation relating to loans made to Wellstat Diagnostics by PDL. RTTNews

08:37AM EDT PDL Biopharma Enters Into Settlement Agreement With Wellstat; Wellstat Parties To Pay $7.5M Upon Signing Of Deal And Either $5M By Feb. 10, 2021 And $55M By July 26, 2021; Or $67.5M By July 26, 2021 Benzinga

08:32AM EDT PDL BioPharma Enters Settlement Agreement With Wellstat RTTNews

08:31AM EDT PDL BioPharma Enters Into Settlement Agreement with Wellstat PR Newswire

Aug 6, 2020

05:20PM EDT PDL BioPharma Q2 EPS $(0.43) Down From $(0.04) YoY, Sales $5.20M Down From $7.46M YoY Benzinga

04:14PM EDT PDL BioPharma Q2 Loss/share $0.43 Vs. Loss $0.04 Year Ago RTTNews

04:06PM EDT PDL BioPharma Reports 2020 Second Quarter Financial Results PR Newswire

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 30, 2020

04:06PM EDT PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, PR Newswire

08:52AM EDT PDL BioPharma, Inc. (PDLI) announced Thursday the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA to Stanley Capital for up to $48.25 million in cash. RTTNews

08:34AM EDT PDL BioPharma Agrees To Divest Noden Pharmaceutical Business To Stanley Capital For $48.25 Mln Cash RTTNews

08:33AM EDT PDL BioPharma Reports Deal To Sell Noden Pharma Business To Stanley Capital For $48.25M In Cash Benzinga

08:31AM EDT PDL BioPharma Enters Into Agreement for the Divestiture of the Noden PR Newswire

Share